TheraRadar
Data updated: May 26, 2026

PRECEDEX (dexmedetomidine hydrochloride)

Trial Activity: Mature
CNS Approved 1999-12-17

Precedex is a sedative used to help adult patients who are intubated and mechanically ventilated in an intensive care setting. It can be administered for up to 24 hours and is often used as patients transition through the process of having their breathing tubes removed. This medication also provides sedation for non-intubated adults during surgical procedures and for pediatric patients as young as one month old undergoing non-invasive procedures.

Source: FDA Label • Pfizer

How PRECEDEX Works

This medication works by acting as a selective alpha 2-adrenergic agonist within the central nervous system to produce sedative effects. While it primarily targets alpha 2 receptors at low to medium doses, it can also activate alpha 1 receptors if it is administered too rapidly or at very high doses.

Development Insights

University of Maryland, Baltimore conducting 1 trials (14%)
10 indications explored (Broad Platform)
traumatic brain injury (1 trials)
premedication (1 trials)
liver transplantation (1 trials)
4
Indications
--
Phase 3 Trials
1
Priority Reviews
26
Years on Market

Details

Status
Prescription
First Approved
1999-12-17
Patent Cliff
2032

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: DEXMEDETOMIDINE HYDROCHLORIDE

PRECEDEX Approval History

2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
105 FDA actions from 1999 to 2026 · 3 indication expansions
May 2026 SUPPL
Label · Labeling
Oct 2024 SUPPL
Update
Dec 2022 SUPPL
Efficacy

What PRECEDEX Treats

1 indications

PRECEDEX is approved for 1 conditions since its original approval in 1999. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Sedation
Source: FDA Label

PRECEDEX Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

MoA expansion candidates

1

Same target(s), different indications — where else is this mechanism being explored?

Indication competitors

2

Same indication, different mechanism — what else might this patient receive?

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to PRECEDEX

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

DEXMEDETOMIDINE HYDROCHLORIDE
DEXMEDETOMIDINE HYDROCHLORIDE
1 shared
Teva
Shared indications:
Sedation
FLUMAZENIL
FLUMAZENIL
1 shared
Baxter
Shared indications:
Sedation
PROPOFOL
PROPOFOL
1 shared
Baxter
Shared indications:
Sedation
📋

Clinical Trial Registry

28 trials
Trial Sponsor ID Phase Status Title
NCT04772222 DICE results posted 136561 Ph 2 completed Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial)
NCT05793060 DTH: 23001 Ph 4 recruiting Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Intermediate Cervical Plexus Block
NCT06575530 IIT2024-001-002 Ph 4 recruiting Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients
NCT06417125 K2024-01-006 Ph 4 completed Intranasal Dexmedetomidine Versus Oral Midazolam Premedication for Postoperative Negative Behavior Changes in Children
NCT03708315 DEX 2000023998 Ph 1 completed BXCL501 for Agitation in Schizophrenia
NCT06720220 Airway topicalization Ph 3 completed Role of Airway Topicalization in Awake Fiberoptic Intubation
NCT04824144 339633386643463 Ph 1, Ph 2 recruiting Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care
NCT06808295 DCR 24-11-17-6-5 Ph 1 recruiting Dexmedetomidine an Effective Drug in Reducing Anesthetic Requirements in External Dacrocystorhinostomy (DCR) Patients
NCT04042727 C-RAD results posted IRB2019-00250 Ph 2, Ph 3 terminated Controlling Rapid Atrial Fibrillation With Dexmedetomidine
NCT05552391 N-88-2022 Ph 4 completed Dexametomedine Versus Ketamine as an Adjuvant in Erector Spinae Block for Perioperative Thoracotomy Pain Control
NCT05993975 SAbbas Ph 4 completed Effects of Intrathecal Dexmedetomidine as an Adjuvant to Low Dose Hyperbaric 0.5% Bupivacaine
NCT01007773 HP-00042821 PRE-08-019 Ph 2 withdrawn Safety of Dexmedetomidine in Severe Traumatic Brain Injury
NCT03078946 results posted 1775 Ph 4 completed Dexmedetomidine Versus Morphine and Midazolam in Prevention and Treatment of Delirium After Adult Cardiac Surgery
NCT03530371 17-HPNCL-02 Ph 3 completed Intranasal Dexmedetomidine for Sedated Hearing Testing
NCT04971759 17300618 Ph 2, Ph 3 completed Dexmedetomidine to Levobupivacaine for Transversus Abdominis Plane Block in Elderly Patients Undergoing Inguinal Hernia Repair Surgery
NCT04968392 17300626 Ph 2, Ph 3 completed Single-shot Adductor Canal Block With Levobupivacaine and Dexmedetomidine in Total Knee Arthroplasty
NCT01438957 results posted DEX-303 Ph 3 completed Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation
NCT03290625 PV0939-2017 Ph 4 completed Intranasal Sedation With Dexmedetomidine and Ketamine in Pediatric Dentistry (NASO II)
NCT03357718 2017/18 Ph 4 completed Oral Dexmedetomidine vs Midazoam For Premedication
NCT04027829 1905-188-1037 Ph 2 completed Pharmacokinetics-pharmacodynamics and Safety of Dexmedetomidine in Children
NCT02245256 1407-114-596 Ph 4 completed Efficacy of Low-dose Dexmedetomidine to Prevent Delirium in Liver Transplant Patients
NCT03940469 IBBB Interscalene Dexmedetomidine Ph 4 completed Dexmedetomidine Versus Dexamethasone With Levobupivacaine in Interscalene Block
NCT02757625 results posted C0801017 ZIN-DEX-1506 Ph 3 completed Study of DA-9501 In Pediatric Subjects In The Intensive Care Unit
NCT03479216 results posted U1111-1211-1791 Ph 4 completed Comparison of Intra-articular Dexmedetomidine and Magnesium in Postoperative Pain
NCT02734940 results posted HM20004692 Ph 4 terminated Multimodal Analgesia in Cardiac Surgery (Pilot Study)
NCT01070680 a004c 2009-014862-25 Ph 4 completed Dexmedetomidine Versus Placebo in Endoscopic Retrograde Cholangiopancreatography (ERCP) Sedation
NCT00691886 2008-011 Ph 4 withdrawn Safety and Efficacy of Intravenous (IV) Dexmedetomidine During Flexible Bronchoscopy and Endobronchial Ultrasound
NCT00848991 01 Ph 3 completed Comparison of Propofol to Precedex With Propofol for Emergence and Recovery in Patients Having Craniotomy Surgery
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PRECEDEX FDA Label Details

Indications & Usage

FDA Label (PDF)

PRECEDEX is indicated for the treatment of Sedation.

View full patent landscape →
13 OB patents · 1 families · 72 international docs across 37 countries

PRECEDEX Patents & Exclusivity

Latest Patent: Jul 2032

Patents (13 active)

US8455527*PED Expires Jul 4, 2032
US8242158*PED Expires Jul 4, 2032
US8338470*PED Expires Jul 4, 2032
US8648106*PED Expires Jul 4, 2032
US9320712*PED Expires Jul 4, 2032
US9616049*PED Expires Jul 4, 2032
US8455527 Expires Jan 4, 2032
US9616049 Expires Jan 4, 2032
US8242158 Expires Jan 4, 2032
US10016396 Expires Jan 4, 2032
US8338470 Expires Jan 4, 2032
US8648106 Expires Jan 4, 2032
US9320712 Expires Jan 4, 2032
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for PRECEDEX

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2032
  • 190 active patents

Trial Analysis

  • 7 total trials
  • Stage: Mature

Competitive Landscape

  • 3 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment